Loading…
Back To Schedule
Wednesday, June 17 • 4:00pm - 5:00pm
#339 SL: The Development of Novel Digital Endpoints

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Tweet Share
Component Type: Forum
Level: Intermediate
CE: ACPE 1.00 Knowledge UAN: 0286-0000-20-617-L04-P; CME 1.00; IACET 1.00; RN 1.00

This session will be used to present two examples of novel digital endpoint development with live chat and Q&A discussion to follow.

Learning Objectives

Discuss the novel digital development framework through industry examples; Identify the concept of interest, the context of use, and the design of validation will be included.

Chair

Michelle Crouthamel, PhD

Speaker

Itching for Feedback: Framework for Qualifying Novel Digital Outcomes
Robert Mather, PhD

The Development of Novel Digital Endpoints
Rinol Alaj, MBA

The Development of Novel Digital Endpoints
Sara Hamon, PhD


Speakers
avatar for Michelle Crouthamel

Michelle Crouthamel

Head, Digital Science, Global Clinical Development, AbbVie, Inc., United States
Michelle Crouthamel is a recognized industry leader who integrates digital health in pharmaceutical development and collaborates broadly with academics, tech, consortia, and health authorities to create impacts. As the Head of Digital Science at AbbVie, Michelle leads digital strategy... Read More →
avatar for Rinol Alaj

Rinol Alaj

Director, COA and Innovation, Regeneron; Representative, TransCelerate Biopharmaceuticals
Rinol’s professional focus is centered around integrated Innovation, design thinking, and clinical operation with 15 years of experience in startup and pharma industry. Savvy, results-oriented leader with proven success in transforming and building eCOA organizations from the ground... Read More →
avatar for Sara Hamon

Sara Hamon

Director, Precision Medicine Quantitative Translational Sciences, Regeneron
Sara is the head of Precision Medicine Quantitative Translational Sciences. Her group designs and performs biomarker analysis on both traditional biomarkers such a genetics and transcriptomics , and non-traditional biomarkers such as data collected from wearables and imaging. Her... Read More →
avatar for Robert Mather

Robert Mather

Executive Director, Early Clinical Development, Pfizer Inc
Joe has over twenty years of pharmaceutical research and clinical development experience. Joe joined the Digital Medicine team after tenures with both Pfizer and Astra Zeneca’s research & development organizations where he led groups focused on late stage research and early clinical... Read More →

Wednesday June 17, 2020 4:00pm - 5:00pm EDT
TBD Virtual Event Horsham, PA 19044
  02: ClinTrials -ClinOps, Forum